5 days ago
GSK plc (NSE: GSK) on Wednesday agreed to acquire 35Pharma Inc. for $950 million.
35Pharma is a Canada-based, private, clinical-stage biopharmaceutical company specializing in the development of novel protein-based therapeutics.
The acquisition includes HS235, an investigational medicine that has completed phase 1 healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
PH is marked by high blood pressure in the lungs. Early symptoms are breathlessness, fatigue, and chest pain, leading to heart failure as the disease progresses.
It affects approximately 82 million people worldwide across multiple disease forms.
Market Outlook and Therapeutic Differentiation
By 2032, the global market for PH therapies is forecast to reach $18 billion, with activin signalling inhibitors expected to account for 50%.
HS235 targets the activin receptor signalling pathway, a clinically validated therapeutic target in PAH.
HS235 is designed with enhanced selectivity, reducing binding to BMP9 and ...
